Metixene

Metixene (Piperidine) is an anticholinergic and antiparkinsonian agent. Metixene potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene can be used for the research of parkinsonian[1][2][3].

Product Specifications

CAS Number

[4969-02-2]

UNSPSC

12352005

Hazard Statement

H302-H410

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/metixene.html

Solubility

10 mM in DMSO

Smiles

CN1CC(CC2C3=C(SC4=C2C=CC=C4)C=CC=C3)CCC1

Molecular Formula

C20H23NS

Molecular Weight

309.47

Precautions

P264-P270-P273-P330-P391-P501

References & Citations

[1]Syvälahti EK, et al. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol. 1988 Feb;62 (2) :90-4. |[2]J. Hagenah, et al. Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence. , 106 (3-4), 301–307. doi:10.1007/s007020050159|[3]S L Levin, et al. Dualism in the effect of cholinolytics upon the human parotid gland deprived of parasympathetic control. Int J Clin Pharmacol Res. 1986;6 (5) :429-39.